Michael Pisetsky Sells 3,328 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,328 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $17.41, for a total transaction of $57,940.48. Following the sale, the senior vice president owned 251,896 shares in the company, valued at approximately $4,385,509.36. This trade represents a 1.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

SiBone Trading Up 1.3%

SIBN traded up $0.24 during trading on Wednesday, hitting $18.60. The company’s stock had a trading volume of 472,223 shares, compared to its average volume of 442,797. SiBone has a twelve month low of $11.70 and a twelve month high of $20.05. The stock has a market cap of $807.05 million, a PE ratio of -36.47 and a beta of 0.81. The firm’s 50 day moving average price is $15.40 and its 200-day moving average price is $16.72. The company has a debt-to-equity ratio of 0.21, a current ratio of 7.97 and a quick ratio of 6.62.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. The business had revenue of $48.66 million for the quarter, compared to analysts’ expectations of $46.67 million. SiBone has set its FY 2025 guidance at EPS. On average, analysts expect that SiBone will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On SiBone

A number of hedge funds have recently made changes to their positions in SIBN. ANTIPODES PARTNERS Ltd acquired a new position in shares of SiBone during the first quarter worth approximately $34,000. State of Alaska Department of Revenue bought a new stake in SiBone during the 3rd quarter valued at $39,000. State of Wyoming bought a new stake in SiBone during the 2nd quarter valued at $55,000. Canada Pension Plan Investment Board acquired a new position in SiBone during the 2nd quarter worth $68,000. Finally, Virtus Advisers LLC bought a new position in shares of SiBone in the first quarter worth $58,000. Institutional investors own 98.11% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Truist Financial dropped their target price on SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research report on Wednesday, October 8th. Cantor Fitzgerald set a $25.00 target price on shares of SiBone and gave the stock an “overweight” rating in a research report on Monday, August 11th. Finally, Wall Street Zen downgraded shares of SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, SiBone presently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.